Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Medical Device

MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia

Fineline Cube Sep 28, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Deals

Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization

Fineline Cube Sep 28, 2022

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...

Company Drug

Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China

Fineline Cube Sep 28, 2022

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...

Company Drug

Fosun Pharma Launches 20ml SPSB Liquid Product in US Market

Fineline Cube Sep 28, 2022

Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...

Company

Merck’s Gabor Outlines AI and Biomedicine Strategy in China

Fineline Cube Sep 28, 2022

Allan Gabor, president of Merck KGaA China and executive vice president of Merck Electronics, shared...

Company Deals

Luye Pharma Grants ICI Pakistan Distribution Rights for Schizophrenia Drug Seroquel

Fineline Cube Sep 28, 2022

China-based Luye Pharma Group has reportedly handed over the distribution and marketing rights for its...

Company Medical Device

Sino Medical Sciences Gains Approval for Drug-Eluting Stent System

Fineline Cube Sep 27, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received market...

Company Drug

Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China

Fineline Cube Sep 27, 2022

The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...

Company Drug

Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study

Fineline Cube Sep 27, 2022

China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...

Company

YiChang HEC Reports Strong Recovery in 2022 Interim Results

Fineline Cube Sep 27, 2022

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...

Company

Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report

Fineline Cube Sep 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of...

Company Deals Drug

Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China

Fineline Cube Sep 27, 2022

Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...

Company

Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute

Fineline Cube Sep 27, 2022

Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...

Company Deals

Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment

Fineline Cube Sep 27, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...

Company Deals

Ubrigene Raises Hundreds of Millions in Series C Financing Round

Fineline Cube Sep 27, 2022

Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...

Company Medical Device

China’s First Proton Therapy System Approved by NMPA

Fineline Cube Sep 27, 2022

The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...

Company Drug

Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296

Fineline Cube Sep 27, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...

Company Drug

Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19

Fineline Cube Sep 27, 2022

China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....

Company

China Resources Pharma Reports Strong Interim Results Amid COVID-19

Fineline Cube Sep 27, 2022

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...

Company Deals

Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development

Fineline Cube Sep 27, 2022

Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...

Posts pagination

1 … 644 645 646 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.